Can [18F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer?

Abdom Radiol (NY). 2020 Feb;45(2):301-306. doi: 10.1007/s00261-019-02268-w.

Abstract

Purpose: To evaluate whether PET/CT could be used to assess the extent of colorectal peritoneal metastases.

Methods: All patients who underwent a PET/CT scan before a CRS-HIPEC procedure between January 1, 2010 and December 31, 2013 were retrospectively included (n = 35). Two nuclear medicine physicians (observer 1 and observer 2) separately reviewed the scans on intraperitoneal abnormalities. A simplified PCI was used to compare the extent of rPCI versus sPCI.

Results: Included patients had a median age of 60.6 years. Histology of primary tumors were 51.5% adenocarcinomas, 37.1% mucinous adenocarcinoma, and 11.4% SRCC. Median sPCI was 9.5 (5.0-11.8) and median rPCI was 5.0 (3.0-7.0) for observer 1 and 4.0 (3.0-6.0) for observer 2 (p = 0.02 and p = 0.01, respectively). When compared to the surgical data, PET/CT showed a poor correlation for assessing the extent of PC for both adenocarcinoma (observer 1 rho - 0.17, p = 0.51 and observer 2 rho 0.13, p = 0.61) as well as mucinous carcinoma or SRCC (observer 1 rho 0.44, p = 0.08 and observer 2 rho 0.38, p = 0.14).

Conclusion: PET/CT underestimates the extent of PC during surgery in both mucinous and non-mucinous CRC and is not recommended for intraperitoneal tumor scoring.

Keywords: Colorectal cancer; HIPEC; Peritoneal carcinomatosis; [18F]fluorodeoxyglucose positron emission tomography.

MeSH terms

  • Colorectal Neoplasms / pathology*
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Peritoneal Neoplasms / diagnostic imaging*
  • Peritoneal Neoplasms / secondary*
  • Positron Emission Tomography Computed Tomography / methods*
  • Preoperative Period
  • Radiation Dosage
  • Radiopharmaceuticals
  • Retrospective Studies

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18